Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics presents updated FID-007 Phase 2 data at ASCO 2026 meeting

Neutral Impact 3 of 5 other Written later

Fulgent Genetics said it presented updated preliminary Phase 2 data for its drug candidate FID-007 combined with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma at the ASCO 2026 Annual Meeting. The company reported an objective response rate of 61.9% and median progression-free survival of 6.7 months, and said a Phase 3 study is planned. The filing contains no financial results, so the update concerns the company's therapeutic pipeline rather than current earnings.

Key points

  • Presentation scheduled June 1, 2026, from 4:30 p.m. to 6:00 p.m. CDT in Chicago, as Abstract #6020 at ASCO 2026
  • Reported objective response rate of 61.9%, median progression-free survival of 6.7 months, and median duration of response of 7.4 months
  • One-year overall survival of 63.4%, based on data with an April 16, 2026 cutoff from a Phase 2 study (NCT06332092)
  • A Phase 3 study is planned; slides are to be posted on the investor relations website after the presentation

The filing

CompanyFulgent Genetics, Inc. (FLGT)
Form8-K, current report
Filed with the SECJun 1, 2026, 7:07 PM ET
Accession number0001674930-26-000028

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.